ArticleBMC cancer2015

Proteoglycan-based diversification of disease outcome in head and neck cancer patients identifies NG2/CSPG4 and syndecan-2 as unique relapse and overall survival predicting factors.

Anna Farnedi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.